NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) is emerging as one of the most profitable stocks because of its robust financial performance and strategic growth initiatives. In Q2 2025 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Today, Takeda Canada Inc. ("Takeda") announced that, for the third consecutive year, it has received Top Employer® certification for 2025. Takeda is one of just 17 companies that received global ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the ...

Ballentine Partners LLC grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 24.3% in the 4th quarter, according to the company in its most recent filing ...

Global biopharmaceutical company Takeda has launched an innovation capability centre (ICC) in Bengaluru, India, joining existing facilities in Slovakia and Mexico. The Bengaluru ICC will focus on ...